marked.bio

PARP inhibitor · small molecule

fluzoparib

4 active trials across 2 of our biomarkers, targeting PARP. Not approved for any biomarker on marked.bio yet.

Also known as SHR-3162.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 4 10 Phase 3
BRAF V600E 0 1 –

Trials

4 of 11 trials shown

  1. Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

    Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Started 2024Primary completion 2031-03 NCT06255392

    fluzoparibapatinibcapecitabinevinorelbineeribulingemcitabinepaclitaxel

    3) The patient's HRD test was positive (definition: BRCA1/2 mutation, or HRD score greater than or equal to 42 points)

    BRCA1/2 mutationFludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer

  2. Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

    Recruiting Phase 2 Qilu Hospital of Shandong University Started 2024Primary completion 2026-08 NCT06735326

    fluzoparibbevacizumab FDA EUpaclitaxelcarboplatin

    Confirmed germline BRCA1/2 mutations by professional genetic testing.

    BRCA1/2 mutationOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

  3. Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

    Recruiting Phase 2 Ying Lin Started 2022Primary completion 2024-06 NCT05761470

    camrelizumabfluzoparibnab-paclitaxel

    HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D g…

    BRCA1/2 mutationStatus may be outdated, last updated 2023-03-09Her-2 Negative Breast Cancer, HRR Gene Mutation

  4. Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

    Recruiting Phase 2 Peking University People's Hospital Started 2022Primary completion 2027-04 NCT05576389

    camrelizumabfluzoparib

    Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

    BRCA1/2 mutationGermline BRCA-mutated HER2-negative Breast Cancer